 |
|
|
| |
Early versus Delayed Hepatitis C Treatment Provides Increased Health Benefits at Lower Costs: A Pan-Genotypic Cost-Effectiveness Analysis Set in Scotland
|
| |
| |
risk of HCC reduced from 35% to 1.8% if treated in F0-1 vs F4, risk of liver related death decreased from 9.1% to 3.8% if treated in F0-1
Reported by Jules Levin
EASL - European Association for the
Study of the Liver (EASL) Paris, France 11 - 15 April 2018
Brett Pinsky1, Dominic Mitchell2, Yuri Sanchez Gonzalez1, Scott Johnson2; Sammy Saab3
1AbbVie, Inc., North Chicago, IL, USA; 2Medicus Economics, Boston, MA, USA; 3UCLA Medical Center, Los Angeles, CA, USA
|
| |
|
|
|
|
|
